Screener
Regenxbio RGNX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Regenxbio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336725
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Maturities of marketable debt securities | 136,882 | 136,020 |
| Sales of marketable debt securities | 11,465 | — |
| Purchases of property and equipment | (1,995) | (1,415) |
| Net cash provided by (used in) investing activities | 136,513 | (95,693) |
| Cash flows from financing activities | ||
| Proceeds from exercise of stock options | 197 | 228 |
| Taxes paid related to net settlement of stock-based awards | (828) | (510) |
| Proceeds from issuance of common stock under employee stock purchase plan | 648 | 307 |
Item 1. Financial Statements.
FAQ
- What is Regenxbio's investing cash flow?
- Regenxbio (RGNX) reported investing cash flow of $65.93M in Q2 2026.
- How has Regenxbio's investing cash flow changed year-over-year?
- Regenxbio's investing cash flow increased by 146.9% year-over-year, from -$140.44M to $65.93M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Regenxbio's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude